MOLECULAR PARTNERS AG (MOLN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in CHF.

Revenue Annual

0 2M 4M 6M 2024: 5M 2025: 0 2024 2025

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M 2024: -61.2M 2025: -58.1M 2024 2025

Net Income Annual

-75M -50M -25M 0 25M 50M 75M 2024: -54M 2025: -61.7M 2024 2025

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M 2024: -59.2M 2025: -51.3M 2024 2025

Free Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M 2024: -60M 2025: -52M 2024 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M 2024: 34M 2025: 37.3M 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.